CytoMed Therapeutics (GDTC) chair discloses 24.3% share stake

Rhea-AI Filing Summary

An amended ownership report for CytoMed Therapeutics Ltd shows that Chairman and Director Choo Chee Kong beneficially owns 2,899,746 ordinary shares, representing 24.30% of the issuer’s 11,934,908 ordinary shares outstanding as of the reported date.

The holdings comprise 2,075,310 shares deemed owned through Glorious Finance Limited, 194,112 shares through EP Capital Inc., and 630,324 shares held directly. He has sole voting and dispositive power over 824,436 shares and shared power over 3,773,291 shares. Between July 14 and July 20, 2026, he acquired 200,000 shares from Teoh Teik Kee at $1.50 per share, for $300,000, using personal funds via a brokerage account. The shares were obtained via capital contributions and open-market purchases for investment purposes. The disclosure notes that shareholders of Glorious Finance may be deemed a Section 13(d)(3) group due to shared voting and dispositive power, though there is no formal voting agreement.

Filing Explained

This Schedule 13D/A records an ownership update and says Choo Chee Kong has no current plan or proposal regarding the listed control-related matters; as chairman and director, he may still be asked to discuss or vote on them.

Key Figures

Beneficial ownership: 2,899,746 ordinary shares % of class: 24.30 % Shares outstanding: 11,934,908 ordinary shares +5 more

8 metrics

Beneficial ownership 2,899,746 ordinary shares Ordinary shares beneficially owned by Choo Chee Kong

% of class 24.30 % Portion of CytoMed Therapeutics ordinary shares represented by beneficial ownership

Shares outstanding 11,934,908 ordinary shares Ordinary shares outstanding used to calculate ownership percentage

Recent shares acquired 200,000 ordinary shares Aggregate purchased on July 14, 2026 and July 20, 2026 from Teoh Teik Kee

Purchase price $1.50 per share Price paid per ordinary share in July 2026 purchases

Total consideration $300,000 Aggregate amount paid for 200,000 ordinary shares

Glorious Finance holdings 3,773,291 ordinary shares CytoMed shares held by Glorious Finance Limited, of which 55% interest is attributed

Ownership in Glorious Finance 55 % Equity stake held by Choo Chee Kong in Glorious Finance Limited

Key Terms

beneficially owns, dispositive power, Section 13(d)(3), Rule 10b-5

4 terms

beneficially owns regulatory

"the Reporting Person beneficially owns 2,899,746 Ordinary Shares"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

dispositive power regulatory

"The Reporting Person has sole voting and dispositive power over 824,436 Ordinary Shares"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Section 13(d)(3) regulatory

"may be deemed to be acting as a group under Section 13(d)(3)"

Rule 10b-5 regulatory

"transactions were conducted in compliance with the Issuer's insider trading policy and Rule 10b-5"

A U.S. securities rule that makes it illegal to lie, omit important facts, or use deceptive practices when buying or selling stocks and other securities. Think of it as a sports referee rule that keeps the playing field fair: investors rely on truthful information to decide whether to buy or sell, and violations can lead to lawsuits, fines, or forced returns of profits, which can affect a company’s stock price and investor confidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/24/2026 - 12:42 PM Accepted by SEC EDGAR 07/24/2026 - 12:42 PM Learn about SEC filing dates

FAQ

What stake in CytoMed Therapeutics (GDTC) does Choo Chee Kong report owning?

He reports beneficial ownership of 2,899,746 ordinary shares of CytoMed Therapeutics, representing 24.30% of the company’s 11,934,908 ordinary shares outstanding as of the reported date.

How many CytoMed Therapeutics (GDTC) shares did Choo Chee Kong recently buy and at what price?

He acquired an aggregate of 200,000 ordinary shares, split into 100,000 on July 14, 2026 and 100,000 on July 20, 2026, from Teoh Teik Kee at $1.50 per share, totaling $300,000 using personal funds.

How are Choo Chee Kong’s CytoMed Therapeutics (GDTC) holdings structured?

His beneficial stake includes 2,075,310 shares through Glorious Finance Limited, 194,112 shares via EP Capital Inc., and 630,324 shares held directly, reflecting both indirect and direct ownership interests.

What voting power does Choo Chee Kong have over CytoMed Therapeutics (GDTC) shares?

He has sole voting and dispositive power over 824,436 shares and shared voting and dispositive power over 3,773,291 shares, reflecting both personal holdings and positions held through affiliated entities.

For what purpose has Choo Chee Kong acquired CytoMed Therapeutics (GDTC) shares?

He acquired his CytoMed shares for investment purposes, either in exchange for capital contributions to the issuer or via public open-market purchases using personal funds, while serving as Chairman and Director.

Were Choo Chee Kong’s CytoMed (GDTC) share purchases compliant with trading rules?

The disclosure states that his purchases between July 14 and July 20, 2026 were conducted in compliance with the issuer’s insider trading policy and Rule 10b-5, as amended.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)

CytoMed Therapeutics Ltd

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

Y1R80M106

(CUSIP Number)

Choo Chee Kong
#08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE
Singapore, U0, 149544
65 6250 7738

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/20/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): Y1R80M106

1

Name of reporting person

Choo Chee Kong

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SINGAPORE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 824,436.00
8	Shared Voting Power 3,773,291.00
9	Sole Dispositive Power 824,436.00
10	Shared Dispositive Power 3,773,291.00

11

Aggregate amount beneficially owned by each reporting person

2,899,746.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

24.30 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares
(b)	Name of Issuer: CytoMed Therapeutics Ltd
(c)	Address of Issuer's Principal Executive Offices: #08-22 ONE COMMONWEALTH, 1 COMMONWEALTH LANE, Singapore, SINGAPORE , 149544.
Item 2.	Identity and Background
(a)	Choo Chee Kong
(b)	1 Commonwealth Lane #08-22, Singapore 149544
(c)	The Reporting Person is the Chairman of the Board and Director of the Issuer. The address of the Issuer is 1 Commonwealth Lane #08-22, Singapore 149544
(d)	No
(e)	No
(f)	Singapore
Item 3.	Source and Amount of Funds or Other Consideration
	PF; On July 14, 2026 and July 20, 2026, the Reporting Person acquired an aggregate of 200,000 Ordinary Shares from Teoh Teik Kee pursuant to two Share Purchase Agreements, each for 100,000 Ordinary Shares at a purchase price of $1.50 per share ($300,000 in the aggregate), settled through the Reporting Person's brokerage account with personal funds.
Item 4.	Purpose of Transaction
	Mr. Choo Chee Kong has acquired all of the Ordinary Shares beneficially owned by him (1) in exchange for capital contributions to the Issuer or (2) through public purchases on the open market with his personal funds for investment purposes. The Reporting Person serves as Chairman of the Issuer and is a member of the board of directors of the Issuer and, as a result, may be asked to vote on or discuss matters related to items (a) through (j) of this Item 4 of Schedule 13D with representatives of the Issuer and others. Except as may be set forth herein, the Reporting Person has no current intention, plan or proposal with respect to items (a) through (j) of Item 4 of Schedule 13D.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: the Reporting Person beneficially owns 2,899,746 Ordinary Shares, representing 24.30% of the Issuer's outstanding shares as of the date hereof. This includes: (1) 2,075,310 Ordinary Shares held indirectly through Glorious Finance Limited ("Glorious Finance"), in which Mr. Choo Chee Kong owns a 55% stake. As such, he is deemed to beneficially own 55% of the 3,773,291 shares held by Glorious Finance, while disclaiming ownership of the remainder. These shares were issued in exchange for capital contributions; (2) 194,112 Ordinary Shares held by EP Capital Inc. ("EP Capital"), which Mr. Choo Chee Kong is deemed to beneficially own. These shares were issued in exchange for capital contributions; and (3) 630,324 Ordinary Shares held directly by Mr. Choo Chee Kong, acquired with personal funds. The calculation is based on 11,934,908 Ordinary Shares outstanding as of the date hereof.
(b)	Please refer to Items 7-13 of the Cover Page. The Reporting Person has sole voting and dispositive power over 824,436 Ordinary Shares, and shared voting and dispositive power over 3,773,291 Ordinary Shares.
(c)	Between July 14, 2026 and July 20, 2026, the Reporting Person acquired an aggregate of 200,000 ordinary shares of the Issuer as follows: (i) 100,000 Ordinary Shares on July 14, 2026 and 100,000 Ordinary Shares on July 20, 2026, pursuant to two Share Purchase Agreements with Teoh Teik Kee at $1.50 per share, settled through a brokerage account. All such transactions were conducted in compliance with the Issuer's insider trading policy and Rule 10b-5 under the Securities Exchange Act of 1934, as amended.
(d)	None
(e)	N/A
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The Reporting Person and the remaining shareholders of Glorious Finance Limited may be deemed to be acting as a "group" under Section 13(d)(3) as they share voting and dispositive power over the 3,773,291 Ordinary Shares of the Issuer. However, there is no formal agreement governing their voting or investment decisions. Except as set forth herein, the Reporting Person has no contracts, arrangements, understandings, or relationships with respect to the Issuer's securities requiring disclosure under this Item 6.
Item 7.	Material to be Filed as Exhibits.
	Except as set forth herein, there are no material agreements, contracts, arrangements, or understandings that require filing as exhibits under this Item 7.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Choo Chee Kong

Signature:	/s/ Choo Chee Kong
Name/Title:	Choo Chee Kong / Chairman and Director of CytoMed Therapeutics Limited
Date:	07/24/2026